Natco Pharma

Why did Natco Pharma's share price slip 3% in trade today? Details here

Natco Pharma shares slipped in trade after the company said that the USFDA has issued one (1) observation in the Form-483 for its API manufacturing plant in Mekaguda, Hyderabad.

Stocks to Watch today, June 16, 2025: Ireda, DLF, OMCs, IndusInd Bk

Stocks to Watch today, June 16, 2025: From Ireda to oil-linked stocks, here is a list of few shares that will remain on investors' radar today

Here's why Natco Pharma share price is buzzing in trade on Thursday, May 29

Natco Pharma share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

Delhi HC tells Natco Pharma to pause launch of generic version of Risdiplam

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam

Natco Pharma trades lower for 10th straight day; tanks 40% on weak Q3

The pharma stock hit its lowest level since December 2023 and tanked 52 per cent from its record high level of Rs 1,638.35, touched on September 12, 2024.

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Natco Pharma shares tank 19%, near 52-week low on weak Q3 results

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy business growth in the ensuing quarters

Natco Pharma Q2FY25 results: PAT jumps 83% to Rs 676 cr on robust sales

Natco Pharma on Tuesday said its consolidated net profit jumped 83 per cent on-year to Rs 676 crore in the September 2024 quarter, aided by robust sales. The drug maker reported a net profit of Rs 369 crore in the July-September period of last fiscal. Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, the company said in a regulatory filing. "The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated. The company said its board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25. Shares of the drug firm ended 0.19 per cent down at Rs 1,393.15 apiece on the BSE.

Here's why Natco Pharma share price gained over 4% on October 7; details

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Natco Pharma shares hit all time high, extend gain for second day; details

The Natco Pharma share price has surged nearly 20 per cent in the last one month, and by 92 per cent year to date

Natco Pharma stock rises 3% after subsidiary invests $8 mn in biotech firm

Natco Pharma share price rose after the company on Wednesday announced that its wholly owned Canadian subsidiary, NATCO Pharma Inc, has made an investment of $8 million in eGenesis

Natco Pharma rises 4% after filing ANDA for generic lung cancer drug

Natco Pharma is the first company to have filed a substantially complete ANDA for a generic cancer drug

Natco Pharma stock surges 8%, hits new 52-week high on strong Q4 show

On Monday, Natco Pharma reported a 40.1 per cent year-on-year (YoY) surge in net profit, totaling Rs 386.3 crore in Q4FY23, up from Rs 275.8 crore

Q4 results today: LIC, NMDC, AstraZeneca among 303 firms to post earnings

Q4 FY24 company results: Elgi Equipments, Natco Pharma, Nalco, Goodyear India, and IFB Ind will be releasing their fourth quarter report on May 27

USFDA pulls up Natco Pharma for several violations at Telangana plant

Natco Pharma failed to maintain cleanliness, sterilise equipment and utensils at appropriate intervals at its Telangana-based plant, as per the US health regulator. In the warning letter to the company, US Food and Drug Administration said its investigators observed various violations at the finished pharmaceuticals plant located at Kothur Village in Telangana. The USFDA inspected the facility from October 9 to 18, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the US health regulator noted. It further said: "Your cleaning procedure for your non-dedicated equipment is inadequate." Cross-contamination is not uniform, and the testing of control samples and placebo batches failed to ...

Natco Pharma receives warning letter from USFDA for Telangana plant

Natco Pharma on Tuesday said it has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility. The inspection was conducted by USFDA from October 9 to October 18, 2023. "We wish to inform you that the company has received a warning letter dated April 8, 2024 from the USFDA," the drug firm said in a regulatory filing. The company does not believe that the warning letter will have an impact on supplies or the existing revenues from this facility, it added. "It may cause delay/withholding of pending product approvals from this site," Natco Pharma said. The drug firm will respond to the letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance, it said. A warning letter is issued when the US

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Natco Pharma Q2 results: Net profit surges over 6-fold to Rs 369 cr

Natco Pharma on Tuesday reported an over six-fold jump in its consolidated net profit to Rs 369 crore in the second quarter ended September 30, 2023. The Hyderabad-based drug firm had reported a net profit of Rs 57 crore in the July-September period of last fiscal. Consolidated total revenue rose to Rs 1,061 crore for the period under review, as compared with Rs 453 crore in the year-ago period, Natco Pharma said in a regulatory filing. The company reported strong performance during the quarter due to growth in formulation exports and increased sales in the domestic agrochemical business, it added.

Natco Pharma, Celgene Corp, others sued in US for generic cancer drug

Natco Pharma on Friday said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US. The Hyderabad-based drug firm along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others have been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide. The company believes this matter is without merit, Natco Pharma said in a statement. Breckenridge is the abbreviated new drug application (ANDA) holder and distribution partner for the generic product in the US, it added. Natco Pharma shares were trading 3.13 per cent down at Rs 885.00 apiece on the BSE.